Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 10:39AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.49 Insider Own56.63% Shs Outstand49.12M Perf Week-10.23%
Market Cap189.68M Forward P/E- EPS next Y-0.52 Insider Trans-0.13% Shs Float21.31M Perf Month-23.26%
Income-63.32M PEG- EPS next Q-0.29 Inst Own30.07% Short Float4.64% Perf Quarter-20.90%
Sales96.63M P/S1.96 EPS this Y41.63% Inst Trans3.90% Short Ratio5.33 Perf Half Y4.32%
Book/sh1.09 P/B3.53 EPS next Y37.69% ROA-35.53% Short Interest0.99M Perf Year-48.05%
Cash/sh1.69 P/C2.28 EPS next 5Y- ROE-112.72% 52W Range3.04 - 8.80 Perf YTD-20.90%
Dividend Est.- P/FCF- EPS past 5Y-37.60% ROI-46.55% 52W High-56.14% Beta1.51
Dividend TTM- Quick Ratio2.94 Sales past 5Y23.82% Gross Margin49.92% 52W Low26.97% ATR (14)0.28
Dividend Ex-Date- Current Ratio3.45 EPS Y/Y TTM20.57% Oper. Margin-57.98% RSI (14)28.99 Volatility5.52% 5.88%
Employees330 Debt/Eq1.59 Sales Y/Y TTM29.09% Profit Margin-65.53% Recom1.38 Target Price9.00
Option/ShortYes / Yes LT Debt/Eq1.53 EPS Q/Q55.71% Payout- Rel Volume0.49 Prev Close3.91
Sales Surprise1.34% EPS Surprise18.15% Sales Q/Q24.83% EarningsMar 04 AMC Avg Volume185.38K Price3.86
SMA20-13.15% SMA50-23.41% SMA200-22.46% Trades Volume19,889 Change-1.28%
Date Action Analyst Rating Change Price Target Change
Dec-14-23Initiated Guggenheim Neutral
Jul-05-23Resumed JP Morgan Overweight $18
Feb-02-23Initiated UBS Buy $14
Nov-03-22Initiated CapitalOne Overweight $19
Oct-06-22Initiated Stephens Overweight $16
Jun-22-22Initiated BTIG Research Buy $16
Jan-06-22Resumed Piper Sandler Overweight $23
May-11-21Initiated Piper Sandler Overweight $28
May-11-21Initiated Morgan Stanley Overweight $26
May-11-21Initiated JP Morgan Overweight $23
Apr-05-24 08:00AM
Mar-05-24 09:52AM
Mar-04-24 08:51PM
05:15PM Loading…
Feb-08-24 04:05PM
Feb-07-24 04:13AM
Jan-18-24 08:00AM
Jan-10-24 08:00AM
Jan-08-24 01:07AM
Jan-07-24 08:00AM
08:00AM Loading…
Jan-05-24 08:34AM
Dec-27-23 09:55AM
Dec-20-23 08:05AM
Nov-12-23 10:51AM
Nov-09-23 10:25AM
Nov-08-23 05:51PM
Nov-02-23 08:00AM
Nov-01-23 10:01AM
Oct-31-23 09:00AM
Oct-17-23 10:22AM
Oct-11-23 04:05PM
Sep-19-23 08:00AM
09:56AM Loading…
Aug-17-23 09:56AM
Aug-08-23 12:38PM
Aug-07-23 06:15PM
Aug-06-23 10:57AM
Jul-26-23 04:05PM
Jul-21-23 09:21AM
Jul-12-23 09:55AM
Jul-10-23 10:08AM
Jun-13-23 07:58PM
Jun-12-23 04:05PM
Jun-08-23 12:55AM
Jun-07-23 04:08PM
May-09-23 10:43AM
May-08-23 05:35PM
May-05-23 07:36AM
Apr-27-23 08:00AM
Apr-17-23 12:20PM
Apr-14-23 03:38PM
Apr-12-23 08:00AM
Apr-06-23 08:00AM
Mar-20-23 04:00PM
Mar-09-23 05:17AM
Mar-08-23 07:21AM
Mar-07-23 09:52AM
Mar-06-23 05:35PM
Feb-28-23 08:00AM
Feb-27-23 10:00AM
Feb-10-23 06:36PM
Feb-06-23 08:05AM
Feb-01-23 08:00AM
Jan-08-23 04:00PM
Jan-06-23 08:00AM
Dec-28-22 04:00PM
Dec-15-22 04:00PM
Dec-07-22 05:15AM
Nov-07-22 05:25PM
Nov-03-22 08:05AM
Oct-11-22 08:05AM
Oct-06-22 01:40PM
Aug-31-22 08:05AM
Aug-11-22 05:24PM
Aug-09-22 12:00AM
Aug-08-22 05:55PM
Jul-27-22 08:05AM
Jul-12-22 08:05AM
Jul-01-22 07:53AM
Jun-29-22 07:21AM
Jun-28-22 08:05AM
Jun-16-22 08:41AM
Jun-03-22 06:11AM
Jun-01-22 08:05AM
May-11-22 06:10AM
May-06-22 10:00PM
May-05-22 06:15PM
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McKelligon BrianPresident and CEOMar 20 '24Option Exercise0.307,5002,272239,368Mar 22 05:54 PM
McKelligon BrianPresident and CEOMar 20 '24Sale4.977,50037,243231,868Mar 22 05:54 PM
McKelligon BrianPresident and CEOMar 13 '24Sale4.947,50037,035224,368Mar 14 08:41 PM
McKelligon BrianPresident and CEODec 19 '23Option Exercise0.307,5002,272160,063Dec 20 07:16 PM
McKelligon BrianPresident and CEODec 19 '23Sale4.487,50033,566152,563Dec 20 07:16 PM
McKelligon BrianPresident and CEODec 12 '23Option Exercise0.307,5002,272160,063Dec 14 04:24 PM
McKelligon BrianPresident and CEODec 12 '23Sale4.257,50031,871152,563Dec 14 04:24 PM
McKelligon BrianPresident and CEONov 20 '23Option Exercise0.307,5002,272160,063Nov 22 04:00 PM
McKelligon BrianPresident and CEONov 20 '23Sale4.397,50032,901152,563Nov 22 04:00 PM
Pla FredericChief Operating OfficerSep 07 '23Buy4.6020,00092,01420,000Sep 11 04:00 PM
Raffin Thomas A.DirectorJun 12 '23Buy5.002,020,00010,100,00015,937,535Jun 12 06:15 PM
Winkler MatthewDirectorJun 12 '23Buy5.00203,3881,016,940984,513Jun 12 06:16 PM
SHEPLER ROBERT GDirectorJun 12 '23Buy5.00120,000600,000369,592Jun 12 06:16 PM
Ek John FrederickCFOJun 12 '23Buy5.0020,000100,00020,000Jun 12 06:18 PM
Mendel ScottDirectorJun 12 '23Buy5.0020,000100,00028,500Jun 12 06:17 PM
LAI GOLDMAN MYLADirectorJun 12 '23Buy5.0020,000100,00020,000Jun 12 06:18 PM
McKelligon BrianPresident/CEOJun 06 '23Option Exercise0.305,0001,515157,563Jun 06 09:45 PM
McKelligon BrianPresident/CEOJun 06 '23Sale5.715,00028,537152,563Jun 06 09:45 PM